Sionna Therapeutics (NASDAQ: SION) shares Q3 2025 results in 8-K

Rhea-AI Filing Summary

Sionna Therapeutics, Inc. furnished an update on its latest performance by submitting an 8-K that includes a press release with financial results and business highlights for the quarter ended September 30, 2025. The company describes these quarterly results and operational developments in the press release attached as Exhibit 99.1 to the report.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0002036042FALSE00020360422025-11-052025-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________

FORM 8-K

__________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 05, 2025

__________________________

SIONNA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

__________________________

Delaware			001-42504			84-2801521
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

SIONNA THERAPEUTICS, INC.

21 Hickory Drive, Suite 500

Waltham, MA02451

(Address of principal executive offices, including zip code)

617-819-2020

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

__________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

SION

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On November 5, 2025, Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth under this Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

99.1			Press Release of Sionna Therapeutics, Inc. dated November 5, 2025.
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Sionna Therapeutics, Inc.
Date: November 05, 2025			By:			/s/ Jennifer Fitzpatrick
			Name:			Jennifer Fitzpatrick
			Title:			Chief Legal Officer

FAQ

What did Sionna Therapeutics (SION) report in this 8-K filing?

Sionna Therapeutics furnished an 8-K to provide a press release that announces its financial results and business highlights for the quarter ended September 30, 2025.

Which period do the Sionna Therapeutics (SION) results cover in this update?

The update covers Sionna Therapeutics’ financial results and business highlights for the quarter ended September 30, 2025.

Where can investors find the detailed Q3 2025 results for Sionna Therapeutics (SION)?

The detailed quarterly financial results and business highlights are provided in the press release furnished as Exhibit 99.1 to the 8-K.

Are the Sionna Therapeutics (SION) Q3 2025 results considered filed with the SEC?

The company states that the information under Item 2.02 and in Exhibit 99.1 is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibits are included with this Sionna Therapeutics (SION) 8-K?

The 8-K includes Exhibit 99.1, a press release dated November 5, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Sionna Therapeutics (SION) 8-K report?

The report was signed on behalf of Sionna Therapeutics, Inc. by Jennifer Fitzpatrick, Chief Legal Officer.